Showing 5041-5050 of 8884 results for "".
- Third Pivotal Phase 3 Study Shows Rinvoq Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitishttps://practicaldermatology.com/news/third-pivotal-phase-3-study-shows-rinvoq-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis/2460489/AbbVie's upadacitinib (15 mg and 30 mg, once daily) (Rinvoq) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of Rinvoq in atopic dermatitis. AD Up evaluated the efficacy and safety of both doses of upadaciti
- This Is Why Sarecycline Is So Effective Against Acnehttps://practicaldermatology.com/news/this-is-why-sarecycline-is-so-effective-against-acne/2460488/Researchers at Yale and the University of Illinois-Chicago have discovered how Sarecycline’s unique chemical structure makes it so effective against acne. Unlike other tetracycline drugs, sarecycline binds to messenger RNA (mRNA) in bacterial ribosomes. Sarecycline and other
- Industry Responds to COVID-19: Cyrex Labs Offers Multiple Autoimmune Reactivity Screenhttps://practicaldermatology.com/news/industry-responds-to-covid-19-pyrex-labs-offers-multiple-autoimmune-reactivity-screen/2460484/With the risks associated with COVID-19 and because those with one autoimmune disease have a 25 percent chance of developing another, specialists say it is critical for those with autoimmune disease to use safety measures, good eating habits, and self-care to avoid contracting this or any virus.&
- Genentech’s Tecentriq plus Cotellic and Zelboraf Approved for Advanced Melanomahttps://practicaldermatology.com/news/genentechs-tecentriq-plus-cotellic-and-zelboraf-approved-for-advanced-melanoma/2460483/Tecentriq (atezolizumab) is now approved in combination with Cotellic (cobimetinib) and Zelboraf(vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profil
- Stelara Approved for PsO in Kids Ages 6-11https://practicaldermatology.com/news/stelara-approved-for-pso-in-kids-ages-6-11/2460482/Stelara® (ustekinumab) is now approved for pediatric patients (6-11 years of age) with moderate to severe plaque psoriasis (PsO). Stelara, from The Janssen Pharmaceutical Companies of Johnson & Johnson, targets both interleukin (IL)-12 and IL-23
- Bimekizumab Bests Cosentyx in Achieving Complete Psoriasis Skin Clearancehttps://practicaldermatology.com/news/bimekizumab-bests-cosentyx-in-achieving-complete-psoriasis-skin-clearance/2460478/UCB’s investigational IL-17A and IL-17F inhibitor bimekizumab outperformed the IL-17A inhibitor Cosentyx (secukinumab) in a head-to-head Phase 3 b study of adult patients with moderate-to-severe plaque psoriasis. This is the first head-to-head study comparing a
- Win for MC2 Therapeutics: Wynzora Cream Approved for Adults with Psoriasishttps://practicaldermatology.com/news/win-for-mc2-therapeutics-wynzora-cream-approved-for-adults-with-psoriasis/2460476/FDA has approved Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older. The approval is based on results of the US Phase 3 clinical trial&nbs
- Abbvie's Rinvoq Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitishttps://practicaldermatology.com/news/abbvies-rinvoq-monotherapy-meets-all-primary-and-secondary-endpoints-in-second-phase-3-study-for-atopic-dermatitis/2460475/AbbVie's upadacitinib (Rinvoq) (15 mg and 30 mg, once daily) monotherapy met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis. The co-primary endpoints were at least a 75 percent improvement in the Ecze
- Another New Patent for Alastin Skincarehttps://practicaldermatology.com/news/another-new-patent-for-alastin-skincare/2460473/Alastin Skincare, Inc. received a fourth U.S. Patent from the United States Patent and Trademark Office. The new patent, which incorporates TriHex Technology, is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum
- Mount Sinai Researcher Identifies Single Gene Biomarker to Differentiate Between Atopic Dermatitis and Psoriasishttps://practicaldermatology.com/news/mount-sinai-researcher-identifies-single-gene-biomarker-to-differentiate-between-atopic-dermatitis-and-psoriasis/2460472/Mount Sinai researchers have pinpointed a single gene biomarker, nitride oxide synthase 2 (NOS2) that can distinguish atopic dermatitis (AD) and psoriasis with 100 percent accuracy using adhesive tape strips, a non-invasive alternative to skin biopsy. The study, published in the Jou